Cervical dystonia due to interaction of valproic acid and quetiapine [4]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 396-397

  Habermeyer, Benedikt ^a   Rabovsky, Kristine ^a   Jentzsch, Christoph ^a   Pinard, Katrin ^a   Müller Spahn, Franz ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; QUETIAPINE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ANTEROCOLLIS; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSTONIA; ELECTROENCEPHALOGRAPHY; FEMALE; GRAND MAL SEIZURE; HUMAN; LETTER; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; TORTICOLLIS; VALPROIC ACID;

EID: 34447498647     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264989.63227.82     Document Type: Letter

References (19)

1. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
2. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-369.
3. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother. 2000;1:783-801.
4. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
5. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24:599-606.
6. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry. 2001;62:728-732.
7. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry. 2004;37:243-265.
8. Prueter C, Habermeyer B, Norra C, et al. Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord. 2003;18:712-713.
9. Jonnalagada JR, Norton JW. Acute dystonia with quetiapine. Clin Neuropharmacol. 2000;23:229-230.
10. Nishikawa T, Nishioka S. A case of Meige dystonia induced by short-term quetiapine treatment. Hum Psychopharmacol. 2002;17:197.
11. Desarker P, Sinha VK. Quetiapine-induced acute dystonia and akathisia. Aust N Z J Psychiatry. 2006;40:607-608.
12. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry. 1999;156:796-797.
13. Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia. Am J Psychiatry. 2001;158:1737.
14. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:209-213.
15. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26:486-491.
16. Kohnlein O, Lutz R, Schmauss M, et al. Determining serum concentrations of the modern antipsychotic quetiapine: clinical relevance in therapeutic drug monitoring. Psychiatr Prax. 2004;31:175-177.
17. Wen X, Wang JS, Kivisto KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547-553.
18. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21:81-85.
19. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-339.